🔗 Share this article

An underground market for unapproved slimming medications is propelled by social media fitness personalities and vendors on communication apps, according to recent findings.

Experimental Treatment Gaining Popularity Via Social Media

The experimental drug, which is still in clinical trials, is being advertised by online personalities for its supposed fat-burning effects. Followers are urged to message these accounts directly for supplier links, while also receiving discount codes.

Active Commerce on Messaging Platforms

Additionally, a flourishing trade exists on messaging services, where groups with numerous of members share “before and after” photos, administration instructions and claims of next-day British shipping. Sellers market the drug there before redirecting buyers to WhatsApp for purchases.

Understanding Retatrutide

This medication is an experimental injectable developed by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could help patients lose up to a quarter of their body weight. Nicknamed the “triple G”, the drug is being promoted digitally as the next Ozempic.

Healthcare Experts Voice Concerns

However, physicians and chemists have cautions that the distribution of what remains an unlicensed drug in the UK is a cause for concern and could result in users administering substances of unknown origin.

Some experts stated the demand for retatrutide could be linked to the rising cost of licensed weight loss treatments such as Mounjaro.

Legal Position and Enforcement

Marketing retatrutide on TikTok or Telegram is prohibited in the UK, as it is an unlicensed drug that cannot be promoted or supplied for personal consumption under the British medical regulations.

Some influencers attempt to circumvent the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but advertising and distribution can still violate pharmaceutical, advertising, and consumer laws, potentially leading to penalties, legal action or imprisonment.

Platform Response and Content Elimination

Based on TikTok, the platform has removed violative content and banned associated hashtags and query recommendations. The company said it was dedicated to maintaining the platform safe and investing in strengthening compliance measures.

Digital Trading Operations

Investigations also discovered groups with up to nine thousand participants marketing retatrutide using the platform's built-in discovery tool, which operates like a public directory. Entering “retatrutide” instantly displays channels with thousands of members, populated with images of weight loss, glowing reviews and detailed instructions for preparing or injecting at home.

Within minutes of joining one group, a vendor shared WhatsApp details, where the majority of purchases occur. The vendor provided an instruction manual and guaranteed delivery within two days. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. None asked about weight, health issues or past usage.

Product Details and Pricing

Within these communities, posts display black plastic parcels with postal service stickers, stating to include new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, mixed at residence with sterile water, or ready-to-use injectors typically priced at £160 for 20mg. When questioned how long a pen should last, sellers give conflicting answers varying between a few weeks to “depends on your body”.

Service Moderation and Security Actions

A spokesperson for Telegram stated it actively moderated dangerous content on its platform including material that encouraged the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are administering substances they can’t verify. Although the research behind this drug is valid, these digital versions may not contain what they claim,” said a pharmacy expert, the head of pharmaceutical services at a pharmacy service.

A medical professional of an online medical service connected the increase in interest to recent price rises for approved weight-loss medications such as Mounjaro. “With prices rising, patients are using online platforms. But counterfeit injections are extremely dangerous. You can’t be certain what’s inside or whether the environment they were made in was clean,” she said.

Her staff has already encountered patients injured by self-injection from unverified sources. “We understand the disappointment, but purchasing from Telegram or WhatsApp is taking chances with your well-being,” stated Wyllie. “These substances could be contaminated or improperly measured.”

Manufacturer Statement

A representative from the pharmaceutical company said retatrutide was in third stage research studies and had not been evaluated or approved by any government authority anywhere in the world. “Consequently at this time no one can sell [it] for human use,” they explained, adding that any item “misleadingly claiming itself as a Lilly experimental substance not yet approved … may subject users to possibly significant medical dangers”.